Tetracyclines in malaria.
Gaillard T, Madamet M, Pradines B.
Malar J. 2015 Nov 10;14:445. doi: 10.1186/s12936-015-0980-0.
Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito.
Balta VA, Stiffler D, Sayeed A, Tripathi AK, Elahi R, Mlambo G, Bakshi RP, Dziedzic AG, Jedlicka AE, Nenortas E, Romero-Rodriguez K, Canonizado MA, Mann A, Owen A, Sullivan DJ, Prigge ST, Sinnis P, Shapiro TA.
Nat Commun. 2023 Oct 12;14(1):6415. doi: 10.1038/s41467-023-42030-x.
Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.
Sakura T, Ishii R, Yoshida E, Kita K, Kato T, Inaoka DK.
ACS Infect Dis. 2024 Dec 13;10(12):4115-4126. doi: 10.1021/acsinfecdis.4c00328. Epub 2024 Nov 19.
Antimalarial pyrido[1,2-a]benzimidazoles.
Ndakala AJ, Gessner RK, Gitari PW, October N, White KL, Hudson A, Fakorede F, Shackleford DM, Kaiser M, Yeates C, Charman SA, Chibale K.
J Med Chem. 2011 Jul 14;54(13):4581-9. doi: 10.1021/jm200227r. Epub 2011 Jun 16.
Understanding artemisinin-induced brainstem neurotoxicity.
Genovese RF, Newman DB.
Arch Toxicol. 2008 Jun;82(6):379-85. doi: 10.1007/s00204-007-0252-z. Epub 2007 Oct 31.
The treatment of malaria.
White NJ.
N Engl J Med. 1996 Sep 12;335(11):800-6. doi: 10.1056/NEJM199609123351107.
Coadaptation and malaria control.
Tosta CE.
Mem Inst Oswaldo Cruz. 2007 Jun;102(3):385-404. doi: 10.1590/s0074-02762007005000042.
Plasmodium falciparum: multifaceted resistance to artemisinins.
Paloque L, Ramadani AP, Mercereau-Puijalon O, Augereau JM, Benoit-Vical F.
Malar J. 2016 Mar 9;15:149. doi: 10.1186/s12936-016-1206-9.
Pharmacokinetics of artemisinin-type compounds.
Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P.
Clin Pharmacokinet. 2000 Oct;39(4):255-70. doi: 10.2165/00003088-200039040-00002.
Identifying Fast and Slow-Acting Antimalarial Compounds of Pandemic Response Box Against Blood-Stage Culture of Plasmodium falciparum 3D7.
Rajendran V, Naveen NC.
Curr Microbiol. 2024 Jan 30;81(3):81. doi: 10.1007/s00284-023-03601-9.
